Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Three conventional eye drops versus a single lyophilisate. A comparative bioavailability study].

A Lux1, S Dinslage, R Süverkrüp

  • 1Département d'Ophtalmologie, Université de Cologne, Allemagne.

Journal Francais D'Ophtalmologie
|April 27, 2005
PubMed
Summary

A novel ocular drug delivery device using a single sodium fluorescein lyophilisate application significantly enhanced bioavailability in the anterior eye segment. This innovation offers improved treatment potential for various eye conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Search for Light Pseudoscalar Bosons, Pair-Produced in Higgs Boson Decays in the Four-Electron Final State in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

First Evidence for Mixing-Induced CP Violation in B_{s}^{0}→J/ψϕ(1020) Decays in pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2026
Same author

Observation of Suppressed Charged-Particle Production in Ultrarelativistic Oxygen-Oxygen Collisions.

Physical review letters·2026
Same author

Measurement of D^{0} Meson Photoproduction in Ultraperipheral Heavy Ion Collisions.

Physical review letters·2026
Same author

Micro-SORS and machine learning for the non-invasive reference-free study of subsurface pigment degradation.

The Analyst·2026
Same author

Observation of tWZ Production at the CMS Experiment.

Physical review letters·2026

Area of Science:

  • Ophthalmology
  • Drug Delivery Systems
  • Biopharmaceutics

Background:

  • Conventional eye drops require frequent administration, impacting patient compliance and drug bioavailability.
  • The anterior segment of the eye presents unique challenges for drug delivery due to rapid clearance and limited absorption.
  • Sodium fluorescein is a vital diagnostic tool and therapeutic agent for various ocular conditions.

Purpose of the Study:

  • To evaluate the ocular bioavailability of a novel single-application sodium fluorescein lyophilisate in the human anterior eye segment.
  • To compare the drug delivery efficiency of the lyophilisate device against conventional preservative-free eye drops.
  • To assess the potential of this new delivery system for improved ocular drug therapy.

Main Methods:

Related Experiment Videos

  • A randomized, open-label study involving 22 healthy volunteers comparing a single lyophilisate application to three conventional eye drops in fellow eyes.
  • Fluorophotometry was used to measure sodium fluorescein concentrations in the corneal stroma and anterior chamber.
  • Measurements were taken at multiple time points up to 7 hours post-application, with data analyzed using paired t-tests.

    • Main Results:

    • The lyophilisate group demonstrated significantly higher mean fluorescein concentrations in the cornea and anterior chamber compared to conventional eye drops (p < 0.018).
    • Bioavailability was up to 11 times higher in the cornea and 8.7 times higher in the anterior chamber with the lyophilisate.
    • Elevated concentrations were sustained for up to 7 hours post-application, with minor exceptions.

    Conclusions:

    • A single lyophilisate application successfully delivered a triple dose of sodium fluorescein to the human eye, achieving superior bioavailability.
    • This novel drug delivery device offers enhanced ocular drug exposure in the anterior segment for up to 7 hours.
    • The lyophilisate technology holds promise for improving the treatment of conditions such as glaucoma, infections, and dry eye syndrome.